cytena Bioprocess Solutions co., Ltd.
Update：2025/12/03
Industries
Main Industry
Biotechnology
Main Product/Service
Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Read more at BICO.com
Founded Year
2018
Unified Business No.
50899774
Status
Active
Number of Employees
0
Total Paid-in
Capital
16,551,130 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting.
Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Read more at BICO.com
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
We have over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.
Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Read more at BICO.com
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
We have over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.
